Co-transplantation of hepatic stellate cells and islet cells
A method of inhibiting graft rejection includes isolating Hepatic Stellate Cells from a mammal liver, activating the isolated Hepatic Stellate Cells, and administering a combination of Hepatic Stellate cells and a graft to a mammal.
1. A method of inhibiting islet graft rejection comprising:
isolating Hepatic Stellate Cells from a mammal liver;
activating the isolated Hepatic Stellate Cells;
mixing islet cells with the Hepatic Stellate Cells; and
administering the mixture of the islet cells and the activated Hepatic Stellate Cells to a mammal.
2. The method of claim 1 wherein the islet graft is selected from the group consisting of a xenograft, an allograft, and an autograft.
3. The method of claim 1 wherein the the mixture of the islet cells and the Hepatic Stellate cells comprise the islet cells pelleted with the Hepatic Stellate cells.
4. The method of claim 1 , the Hepatic Stellate cells forming a multiple layered capsule surrounding the islet cells.
5. The method of claim 1 wherein the Hepatic Stellate cells form a coating surrounding the islet cells.
6. The method of claim 1 wherein the Hepatic Stellate cells are isolated from mammal liver non parenchymal cells.
7. The method of claim 1 wherein the isolated Hepatic Stellate cells are activated to express an immune regulatory molecule.
8. The method of claim 7 wherein the immune regulatory molecule comprises B7H1.
9. The method of claim 1 wherein the mixture of the islet cells and the activated Hepatic Stellate cells is administered to a mammal for the treatment of diabetes mellitus.
10. The method of claim 1 wherein the Hepatic Stellate cells are immunologically compatible to the mammal recipient.